nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—PNLIP—exocrine gland—esophageal cancer	0.035	0.114	CbGeAlD
Orlistat—LIPF—digestive system—esophageal cancer	0.0326	0.106	CbGeAlD
Orlistat—DAGLB—bronchus—esophageal cancer	0.0211	0.0688	CbGeAlD
Orlistat—ABHD16A—bronchus—esophageal cancer	0.016	0.0521	CbGeAlD
Orlistat—ABHD12—bronchus—esophageal cancer	0.015	0.0488	CbGeAlD
Orlistat—ABHD16A—trachea—esophageal cancer	0.0144	0.0468	CbGeAlD
Orlistat—DAGLB—lung—esophageal cancer	0.0136	0.0444	CbGeAlD
Orlistat—ABHD12—trachea—esophageal cancer	0.0135	0.0438	CbGeAlD
Orlistat—FASN—bronchus—esophageal cancer	0.0126	0.041	CbGeAlD
Orlistat—PLA2G4A—Raltitrexed—Methotrexate—esophageal cancer	0.0125	1	CbGdCrCtD
Orlistat—PNLIP—digestive system—esophageal cancer	0.0116	0.0377	CbGeAlD
Orlistat—FASN—trachea—esophageal cancer	0.0113	0.0368	CbGeAlD
Orlistat—PLA2G7—lung—esophageal cancer	0.011	0.0358	CbGeAlD
Orlistat—Autonomic neuropathy—Cisplatin—esophageal cancer	0.0107	0.045	CcSEcCtD
Orlistat—ABHD16A—lung—esophageal cancer	0.0103	0.0336	CbGeAlD
Orlistat—PNLIP—lung—esophageal cancer	0.00967	0.0315	CbGeAlD
Orlistat—ABHD12—lung—esophageal cancer	0.00967	0.0315	CbGeAlD
Orlistat—DAGLB—lymph node—esophageal cancer	0.00931	0.0303	CbGeAlD
Orlistat—FASN—lung—esophageal cancer	0.00811	0.0264	CbGeAlD
Orlistat—PLA2G7—lymph node—esophageal cancer	0.00752	0.0245	CbGeAlD
Orlistat—ABHD16A—lymph node—esophageal cancer	0.00705	0.023	CbGeAlD
Orlistat—ABHD12—lymph node—esophageal cancer	0.00661	0.0215	CbGeAlD
Orlistat—PLA2G4A—bronchus—esophageal cancer	0.00604	0.0197	CbGeAlD
Orlistat—PLA2G4A—smooth muscle tissue—esophageal cancer	0.00591	0.0193	CbGeAlD
Orlistat—Abdominal pain lower—Capecitabine—esophageal cancer	0.00563	0.0237	CcSEcCtD
Orlistat—FASN—lymph node—esophageal cancer	0.00555	0.0181	CbGeAlD
Orlistat—PLA2G4A—trachea—esophageal cancer	0.00543	0.0177	CbGeAlD
Orlistat—Lower respiratory tract infection—Capecitabine—esophageal cancer	0.00524	0.022	CcSEcCtD
Orlistat—Enteritis—Capecitabine—esophageal cancer	0.00524	0.022	CcSEcCtD
Orlistat—Pruritus genital—Capecitabine—esophageal cancer	0.00429	0.018	CcSEcCtD
Orlistat—Reaction gastrointestinal—Methotrexate—esophageal cancer	0.004	0.0168	CcSEcCtD
Orlistat—Diabetic—Methotrexate—esophageal cancer	0.004	0.0168	CcSEcCtD
Orlistat—Enteritis—Methotrexate—esophageal cancer	0.0039	0.0164	CcSEcCtD
Orlistat—PLA2G4A—lung—esophageal cancer	0.0039	0.0127	CbGeAlD
Orlistat—Proctalgia—Capecitabine—esophageal cancer	0.00382	0.0161	CcSEcCtD
Orlistat—Haemorrhoids—Capecitabine—esophageal cancer	0.00305	0.0128	CcSEcCtD
Orlistat—Infection—Carboplatin—esophageal cancer	0.00294	0.0123	CcSEcCtD
Orlistat—Nephropathy—Methotrexate—esophageal cancer	0.0028	0.0118	CcSEcCtD
Orlistat—Hypothyroidism—Capecitabine—esophageal cancer	0.00279	0.0117	CcSEcCtD
Orlistat—Nail disorder—Capecitabine—esophageal cancer	0.00276	0.0116	CcSEcCtD
Orlistat—Appetite absent—Methotrexate—esophageal cancer	0.00268	0.0113	CcSEcCtD
Orlistat—PLA2G4A—lymph node—esophageal cancer	0.00267	0.00869	CbGeAlD
Orlistat—Pain—Carboplatin—esophageal cancer	0.00253	0.0106	CcSEcCtD
Orlistat—Body temperature increased—Carboplatin—esophageal cancer	0.00234	0.00982	CcSEcCtD
Orlistat—Fracture—Methotrexate—esophageal cancer	0.00229	0.00964	CcSEcCtD
Orlistat—Multiple fractures—Methotrexate—esophageal cancer	0.00229	0.00964	CcSEcCtD
Orlistat—Nail disorder—Methotrexate—esophageal cancer	0.00206	0.00864	CcSEcCtD
Orlistat—Polyuria—Cisplatin—esophageal cancer	0.00201	0.00844	CcSEcCtD
Orlistat—Rectal haemorrhage—Capecitabine—esophageal cancer	0.00198	0.00834	CcSEcCtD
Orlistat—Neoplasm—Capecitabine—esophageal cancer	0.00162	0.00681	CcSEcCtD
Orlistat—Urine output increased—Capecitabine—esophageal cancer	0.00162	0.00681	CcSEcCtD
Orlistat—Hypokalaemia—Cisplatin—esophageal cancer	0.00161	0.00675	CcSEcCtD
Orlistat—Breast disorder—Cisplatin—esophageal cancer	0.00159	0.0067	CcSEcCtD
Orlistat—Cramp muscle—Cisplatin—esophageal cancer	0.00159	0.00668	CcSEcCtD
Orlistat—CYP3A4—digestive system—esophageal cancer	0.00154	0.00502	CbGeAlD
Orlistat—Sleep disorder—Capecitabine—esophageal cancer	0.0015	0.00631	CcSEcCtD
Orlistat—Diabetes mellitus—Capecitabine—esophageal cancer	0.0015	0.00628	CcSEcCtD
Orlistat—Pancreatitis—Cisplatin—esophageal cancer	0.00149	0.00628	CcSEcCtD
Orlistat—Sweating increased—Cisplatin—esophageal cancer	0.00149	0.00624	CcSEcCtD
Orlistat—Polyuria—Capecitabine—esophageal cancer	0.00148	0.00622	CcSEcCtD
Orlistat—Abdominal discomfort—Cisplatin—esophageal cancer	0.00146	0.00614	CcSEcCtD
Orlistat—Hepatic failure—Capecitabine—esophageal cancer	0.00145	0.00608	CcSEcCtD
Orlistat—Increased appetite—Capecitabine—esophageal cancer	0.00138	0.00582	CcSEcCtD
Orlistat—Menopausal symptoms—Capecitabine—esophageal cancer	0.00138	0.00579	CcSEcCtD
Orlistat—Thirst—Capecitabine—esophageal cancer	0.00137	0.00574	CcSEcCtD
Orlistat—Dermatitis bullous—Capecitabine—esophageal cancer	0.00136	0.00572	CcSEcCtD
Orlistat—Arthritis—Capecitabine—esophageal cancer	0.00134	0.00562	CcSEcCtD
Orlistat—Renal failure—Cisplatin—esophageal cancer	0.00134	0.00562	CcSEcCtD
Orlistat—Vaginal inflammation—Methotrexate—esophageal cancer	0.00133	0.00561	CcSEcCtD
Orlistat—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00133	0.0056	CcSEcCtD
Orlistat—Osteoarthritis—Capecitabine—esophageal cancer	0.0013	0.00547	CcSEcCtD
Orlistat—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00129	0.0054	CcSEcCtD
Orlistat—Vaginal infection—Methotrexate—esophageal cancer	0.00126	0.00529	CcSEcCtD
Orlistat—Neoplasm—Methotrexate—esophageal cancer	0.00121	0.00507	CcSEcCtD
Orlistat—Urine output increased—Methotrexate—esophageal cancer	0.00121	0.00507	CcSEcCtD
Orlistat—Urinary tract disorder—Cisplatin—esophageal cancer	0.00121	0.00507	CcSEcCtD
Orlistat—Urethral disorder—Cisplatin—esophageal cancer	0.0012	0.00503	CcSEcCtD
Orlistat—Dry skin—Capecitabine—esophageal cancer	0.00119	0.00501	CcSEcCtD
Orlistat—Abdominal pain upper—Capecitabine—esophageal cancer	0.00119	0.00499	CcSEcCtD
Orlistat—Hypokalaemia—Capecitabine—esophageal cancer	0.00118	0.00497	CcSEcCtD
Orlistat—Breast disorder—Capecitabine—esophageal cancer	0.00118	0.00494	CcSEcCtD
Orlistat—Gastritis—Capecitabine—esophageal cancer	0.00115	0.00484	CcSEcCtD
Orlistat—Abdominal distension—Capecitabine—esophageal cancer	0.00113	0.00476	CcSEcCtD
Orlistat—Influenza—Capecitabine—esophageal cancer	0.00112	0.00472	CcSEcCtD
Orlistat—Asthma—Capecitabine—esophageal cancer	0.00112	0.00472	CcSEcCtD
Orlistat—Diabetes mellitus—Methotrexate—esophageal cancer	0.00111	0.00468	CcSEcCtD
Orlistat—Bronchospasm—Capecitabine—esophageal cancer	0.00111	0.00465	CcSEcCtD
Orlistat—Polyuria—Methotrexate—esophageal cancer	0.0011	0.00463	CcSEcCtD
Orlistat—Immune system disorder—Cisplatin—esophageal cancer	0.0011	0.00463	CcSEcCtD
Orlistat—Mediastinal disorder—Cisplatin—esophageal cancer	0.0011	0.00462	CcSEcCtD
Orlistat—Sweating increased—Capecitabine—esophageal cancer	0.00109	0.0046	CcSEcCtD
Orlistat—Alopecia—Cisplatin—esophageal cancer	0.00108	0.00453	CcSEcCtD
Orlistat—Abdominal discomfort—Capecitabine—esophageal cancer	0.00108	0.00453	CcSEcCtD
Orlistat—Hepatic failure—Methotrexate—esophageal cancer	0.00108	0.00453	CcSEcCtD
Orlistat—Malnutrition—Cisplatin—esophageal cancer	0.00106	0.00447	CcSEcCtD
Orlistat—Flatulence—Cisplatin—esophageal cancer	0.00105	0.0044	CcSEcCtD
Orlistat—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00104	0.00439	CcSEcCtD
Orlistat—Muscle spasms—Cisplatin—esophageal cancer	0.00102	0.00429	CcSEcCtD
Orlistat—Infestation—Capecitabine—esophageal cancer	0.001	0.00421	CcSEcCtD
Orlistat—Infestation NOS—Capecitabine—esophageal cancer	0.001	0.00421	CcSEcCtD
Orlistat—Vision blurred—Cisplatin—esophageal cancer	0.001	0.00421	CcSEcCtD
Orlistat—Depression—Capecitabine—esophageal cancer	0.000999	0.0042	CcSEcCtD
Orlistat—Ill-defined disorder—Cisplatin—esophageal cancer	0.000986	0.00414	CcSEcCtD
Orlistat—Renal failure—Capecitabine—esophageal cancer	0.000985	0.00414	CcSEcCtD
Orlistat—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000982	0.00413	CcSEcCtD
Orlistat—Urinary tract infection—Capecitabine—esophageal cancer	0.000974	0.00409	CcSEcCtD
Orlistat—Osteoarthritis—Methotrexate—esophageal cancer	0.000968	0.00407	CcSEcCtD
Orlistat—Malaise—Cisplatin—esophageal cancer	0.000958	0.00403	CcSEcCtD
Orlistat—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000948	0.00398	CcSEcCtD
Orlistat—Convulsion—Cisplatin—esophageal cancer	0.00092	0.00387	CcSEcCtD
Orlistat—Myalgia—Cisplatin—esophageal cancer	0.000904	0.0038	CcSEcCtD
Orlistat—Haemoglobin—Capecitabine—esophageal cancer	0.000904	0.0038	CcSEcCtD
Orlistat—Anxiety—Cisplatin—esophageal cancer	0.000901	0.00379	CcSEcCtD
Orlistat—Hepatitis—Capecitabine—esophageal cancer	0.0009	0.00378	CcSEcCtD
Orlistat—Haemorrhage—Capecitabine—esophageal cancer	0.0009	0.00378	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000898	0.00378	CcSEcCtD
Orlistat—Discomfort—Cisplatin—esophageal cancer	0.000894	0.00376	CcSEcCtD
Orlistat—Pharyngitis—Capecitabine—esophageal cancer	0.000893	0.00375	CcSEcCtD
Orlistat—Urinary tract disorder—Capecitabine—esophageal cancer	0.000888	0.00373	CcSEcCtD
Orlistat—Oedema peripheral—Capecitabine—esophageal cancer	0.000886	0.00372	CcSEcCtD
Orlistat—Urethral disorder—Capecitabine—esophageal cancer	0.000882	0.00371	CcSEcCtD
Orlistat—Breast disorder—Methotrexate—esophageal cancer	0.000875	0.00368	CcSEcCtD
Orlistat—Oedema—Cisplatin—esophageal cancer	0.000867	0.00364	CcSEcCtD
Orlistat—Anaphylactic shock—Cisplatin—esophageal cancer	0.000867	0.00364	CcSEcCtD
Orlistat—Infection—Cisplatin—esophageal cancer	0.000861	0.00362	CcSEcCtD
Orlistat—Nervous system disorder—Cisplatin—esophageal cancer	0.00085	0.00357	CcSEcCtD
Orlistat—Skin disorder—Cisplatin—esophageal cancer	0.000842	0.00354	CcSEcCtD
Orlistat—Hyperhidrosis—Cisplatin—esophageal cancer	0.000838	0.00352	CcSEcCtD
Orlistat—Asthma—Methotrexate—esophageal cancer	0.000837	0.00352	CcSEcCtD
Orlistat—Pancreatitis—Methotrexate—esophageal cancer	0.00082	0.00345	CcSEcCtD
Orlistat—Immune system disorder—Capecitabine—esophageal cancer	0.000813	0.00342	CcSEcCtD
Orlistat—Mediastinal disorder—Capecitabine—esophageal cancer	0.000811	0.00341	CcSEcCtD
Orlistat—Abdominal discomfort—Methotrexate—esophageal cancer	0.000802	0.00337	CcSEcCtD
Orlistat—Alopecia—Capecitabine—esophageal cancer	0.000795	0.00334	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00079	0.00332	CcSEcCtD
Orlistat—Mental disorder—Capecitabine—esophageal cancer	0.000788	0.00331	CcSEcCtD
Orlistat—Malnutrition—Capecitabine—esophageal cancer	0.000783	0.00329	CcSEcCtD
Orlistat—Paraesthesia—Cisplatin—esophageal cancer	0.000779	0.00327	CcSEcCtD
Orlistat—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000778	0.00327	CcSEcCtD
Orlistat—Flatulence—Capecitabine—esophageal cancer	0.000772	0.00324	CcSEcCtD
Orlistat—Dysgeusia—Capecitabine—esophageal cancer	0.000767	0.00322	CcSEcCtD
Orlistat—Back pain—Capecitabine—esophageal cancer	0.000757	0.00318	CcSEcCtD
Orlistat—Decreased appetite—Cisplatin—esophageal cancer	0.000754	0.00317	CcSEcCtD
Orlistat—Muscle spasms—Capecitabine—esophageal cancer	0.000753	0.00316	CcSEcCtD
Orlistat—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000749	0.00315	CcSEcCtD
Orlistat—Infestation NOS—Methotrexate—esophageal cancer	0.000746	0.00314	CcSEcCtD
Orlistat—Infestation—Methotrexate—esophageal cancer	0.000746	0.00314	CcSEcCtD
Orlistat—Depression—Methotrexate—esophageal cancer	0.000744	0.00313	CcSEcCtD
Orlistat—Pain—Cisplatin—esophageal cancer	0.000741	0.00312	CcSEcCtD
Orlistat—Vision blurred—Capecitabine—esophageal cancer	0.000738	0.0031	CcSEcCtD
Orlistat—Renal failure—Methotrexate—esophageal cancer	0.000733	0.00308	CcSEcCtD
Orlistat—Ill-defined disorder—Capecitabine—esophageal cancer	0.000727	0.00305	CcSEcCtD
Orlistat—Feeling abnormal—Cisplatin—esophageal cancer	0.000714	0.003	CcSEcCtD
Orlistat—Malaise—Capecitabine—esophageal cancer	0.000706	0.00297	CcSEcCtD
Orlistat—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000706	0.00297	CcSEcCtD
Orlistat—Vertigo—Capecitabine—esophageal cancer	0.000704	0.00296	CcSEcCtD
Orlistat—Palpitations—Capecitabine—esophageal cancer	0.000692	0.00291	CcSEcCtD
Orlistat—Body temperature increased—Cisplatin—esophageal cancer	0.000685	0.00288	CcSEcCtD
Orlistat—Cough—Capecitabine—esophageal cancer	0.000683	0.00287	CcSEcCtD
Orlistat—Haemoglobin—Methotrexate—esophageal cancer	0.000673	0.00283	CcSEcCtD
Orlistat—Haemorrhage—Methotrexate—esophageal cancer	0.00067	0.00281	CcSEcCtD
Orlistat—Hepatitis—Methotrexate—esophageal cancer	0.00067	0.00281	CcSEcCtD
Orlistat—Chest pain—Capecitabine—esophageal cancer	0.000667	0.0028	CcSEcCtD
Orlistat—Myalgia—Capecitabine—esophageal cancer	0.000667	0.0028	CcSEcCtD
Orlistat—Pharyngitis—Methotrexate—esophageal cancer	0.000665	0.00279	CcSEcCtD
Orlistat—Anxiety—Capecitabine—esophageal cancer	0.000664	0.00279	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000662	0.00278	CcSEcCtD
Orlistat—Urinary tract disorder—Methotrexate—esophageal cancer	0.000661	0.00278	CcSEcCtD
Orlistat—Discomfort—Capecitabine—esophageal cancer	0.000659	0.00277	CcSEcCtD
Orlistat—Urethral disorder—Methotrexate—esophageal cancer	0.000656	0.00276	CcSEcCtD
Orlistat—Dry mouth—Capecitabine—esophageal cancer	0.000652	0.00274	CcSEcCtD
Orlistat—Oedema—Capecitabine—esophageal cancer	0.000639	0.00269	CcSEcCtD
Orlistat—Hypersensitivity—Cisplatin—esophageal cancer	0.000639	0.00268	CcSEcCtD
Orlistat—Infection—Capecitabine—esophageal cancer	0.000635	0.00267	CcSEcCtD
Orlistat—Nervous system disorder—Capecitabine—esophageal cancer	0.000627	0.00263	CcSEcCtD
Orlistat—Asthenia—Cisplatin—esophageal cancer	0.000622	0.00261	CcSEcCtD
Orlistat—Skin disorder—Capecitabine—esophageal cancer	0.000621	0.00261	CcSEcCtD
Orlistat—Hyperhidrosis—Capecitabine—esophageal cancer	0.000618	0.0026	CcSEcCtD
Orlistat—Immune system disorder—Methotrexate—esophageal cancer	0.000605	0.00254	CcSEcCtD
Orlistat—Mediastinal disorder—Methotrexate—esophageal cancer	0.000604	0.00254	CcSEcCtD
Orlistat—Diarrhoea—Cisplatin—esophageal cancer	0.000593	0.00249	CcSEcCtD
Orlistat—Alopecia—Methotrexate—esophageal cancer	0.000592	0.00249	CcSEcCtD
Orlistat—Mental disorder—Methotrexate—esophageal cancer	0.000587	0.00247	CcSEcCtD
Orlistat—Malnutrition—Methotrexate—esophageal cancer	0.000583	0.00245	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000582	0.00245	CcSEcCtD
Orlistat—Insomnia—Capecitabine—esophageal cancer	0.000578	0.00243	CcSEcCtD
Orlistat—Paraesthesia—Capecitabine—esophageal cancer	0.000574	0.00241	CcSEcCtD
Orlistat—Dysgeusia—Methotrexate—esophageal cancer	0.000571	0.0024	CcSEcCtD
Orlistat—Back pain—Methotrexate—esophageal cancer	0.000564	0.00237	CcSEcCtD
Orlistat—Dyspepsia—Capecitabine—esophageal cancer	0.000563	0.00236	CcSEcCtD
Orlistat—Decreased appetite—Capecitabine—esophageal cancer	0.000556	0.00234	CcSEcCtD
Orlistat—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000552	0.00232	CcSEcCtD
Orlistat—Vomiting—Cisplatin—esophageal cancer	0.000551	0.00232	CcSEcCtD
Orlistat—Fatigue—Capecitabine—esophageal cancer	0.000551	0.00232	CcSEcCtD
Orlistat—Vision blurred—Methotrexate—esophageal cancer	0.000549	0.00231	CcSEcCtD
Orlistat—Rash—Cisplatin—esophageal cancer	0.000547	0.0023	CcSEcCtD
Orlistat—Pain—Capecitabine—esophageal cancer	0.000547	0.0023	CcSEcCtD
Orlistat—Dermatitis—Cisplatin—esophageal cancer	0.000546	0.0023	CcSEcCtD
Orlistat—Ill-defined disorder—Methotrexate—esophageal cancer	0.000541	0.00227	CcSEcCtD
Orlistat—Feeling abnormal—Capecitabine—esophageal cancer	0.000527	0.00221	CcSEcCtD
Orlistat—Malaise—Methotrexate—esophageal cancer	0.000526	0.00221	CcSEcCtD
Orlistat—Vertigo—Methotrexate—esophageal cancer	0.000524	0.0022	CcSEcCtD
Orlistat—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000523	0.0022	CcSEcCtD
Orlistat—Nausea—Cisplatin—esophageal cancer	0.000515	0.00216	CcSEcCtD
Orlistat—Cough—Methotrexate—esophageal cancer	0.000509	0.00214	CcSEcCtD
Orlistat—Urticaria—Capecitabine—esophageal cancer	0.000508	0.00213	CcSEcCtD
Orlistat—Abdominal pain—Capecitabine—esophageal cancer	0.000505	0.00212	CcSEcCtD
Orlistat—Body temperature increased—Capecitabine—esophageal cancer	0.000505	0.00212	CcSEcCtD
Orlistat—Convulsion—Methotrexate—esophageal cancer	0.000505	0.00212	CcSEcCtD
Orlistat—Myalgia—Methotrexate—esophageal cancer	0.000496	0.00209	CcSEcCtD
Orlistat—Chest pain—Methotrexate—esophageal cancer	0.000496	0.00209	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000493	0.00207	CcSEcCtD
Orlistat—Discomfort—Methotrexate—esophageal cancer	0.00049	0.00206	CcSEcCtD
Orlistat—Anaphylactic shock—Methotrexate—esophageal cancer	0.000476	0.002	CcSEcCtD
Orlistat—Infection—Methotrexate—esophageal cancer	0.000473	0.00199	CcSEcCtD
Orlistat—Hypersensitivity—Capecitabine—esophageal cancer	0.000471	0.00198	CcSEcCtD
Orlistat—Nervous system disorder—Methotrexate—esophageal cancer	0.000467	0.00196	CcSEcCtD
Orlistat—Skin disorder—Methotrexate—esophageal cancer	0.000462	0.00194	CcSEcCtD
Orlistat—Hyperhidrosis—Methotrexate—esophageal cancer	0.00046	0.00193	CcSEcCtD
Orlistat—Asthenia—Capecitabine—esophageal cancer	0.000459	0.00193	CcSEcCtD
Orlistat—Pruritus—Capecitabine—esophageal cancer	0.000452	0.0019	CcSEcCtD
Orlistat—Diarrhoea—Capecitabine—esophageal cancer	0.000437	0.00184	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000433	0.00182	CcSEcCtD
Orlistat—Insomnia—Methotrexate—esophageal cancer	0.00043	0.00181	CcSEcCtD
Orlistat—Paraesthesia—Methotrexate—esophageal cancer	0.000427	0.0018	CcSEcCtD
Orlistat—Dizziness—Capecitabine—esophageal cancer	0.000423	0.00178	CcSEcCtD
Orlistat—Dyspepsia—Methotrexate—esophageal cancer	0.000419	0.00176	CcSEcCtD
Orlistat—Decreased appetite—Methotrexate—esophageal cancer	0.000414	0.00174	CcSEcCtD
Orlistat—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000411	0.00173	CcSEcCtD
Orlistat—Fatigue—Methotrexate—esophageal cancer	0.00041	0.00172	CcSEcCtD
Orlistat—Pain—Methotrexate—esophageal cancer	0.000407	0.00171	CcSEcCtD
Orlistat—Vomiting—Capecitabine—esophageal cancer	0.000406	0.00171	CcSEcCtD
Orlistat—Rash—Capecitabine—esophageal cancer	0.000403	0.00169	CcSEcCtD
Orlistat—Dermatitis—Capecitabine—esophageal cancer	0.000403	0.00169	CcSEcCtD
Orlistat—Headache—Capecitabine—esophageal cancer	0.0004	0.00168	CcSEcCtD
Orlistat—Feeling abnormal—Methotrexate—esophageal cancer	0.000392	0.00165	CcSEcCtD
Orlistat—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000389	0.00164	CcSEcCtD
Orlistat—Nausea—Capecitabine—esophageal cancer	0.00038	0.0016	CcSEcCtD
Orlistat—Urticaria—Methotrexate—esophageal cancer	0.000378	0.00159	CcSEcCtD
Orlistat—Abdominal pain—Methotrexate—esophageal cancer	0.000376	0.00158	CcSEcCtD
Orlistat—Body temperature increased—Methotrexate—esophageal cancer	0.000376	0.00158	CcSEcCtD
Orlistat—Hypersensitivity—Methotrexate—esophageal cancer	0.000351	0.00147	CcSEcCtD
Orlistat—Asthenia—Methotrexate—esophageal cancer	0.000341	0.00143	CcSEcCtD
Orlistat—Pruritus—Methotrexate—esophageal cancer	0.000337	0.00141	CcSEcCtD
Orlistat—Diarrhoea—Methotrexate—esophageal cancer	0.000326	0.00137	CcSEcCtD
Orlistat—Dizziness—Methotrexate—esophageal cancer	0.000315	0.00132	CcSEcCtD
Orlistat—Vomiting—Methotrexate—esophageal cancer	0.000303	0.00127	CcSEcCtD
Orlistat—Rash—Methotrexate—esophageal cancer	0.0003	0.00126	CcSEcCtD
Orlistat—Dermatitis—Methotrexate—esophageal cancer	0.0003	0.00126	CcSEcCtD
Orlistat—Headache—Methotrexate—esophageal cancer	0.000298	0.00125	CcSEcCtD
Orlistat—Nausea—Methotrexate—esophageal cancer	0.000283	0.00119	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—NOTCH2—esophageal cancer	0.00022	0.000497	CbGpPWpGaD
Orlistat—FASN—Metabolism—PSME2—esophageal cancer	0.00022	0.000497	CbGpPWpGaD
Orlistat—FASN—Metabolism—PSME1—esophageal cancer	0.00022	0.000497	CbGpPWpGaD
Orlistat—PNLIP—Disease—HIF1A—esophageal cancer	0.000216	0.000488	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000215	0.000486	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—TP53—esophageal cancer	0.000214	0.000484	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TP53—esophageal cancer	0.000214	0.000484	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00021	0.000475	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000209	0.000472	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	0.000208	0.00047	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC10A2—esophageal cancer	0.000205	0.000462	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CA1—esophageal cancer	0.000205	0.000462	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	0.000202	0.000456	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—MYC—esophageal cancer	0.000201	0.000454	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000198	0.000446	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	0.000198	0.000446	CbGpPWpGaD
Orlistat—FASN—Disease—TGFBR2—esophageal cancer	0.000197	0.000446	CbGpPWpGaD
Orlistat—PNLIP—Disease—NOS2—esophageal cancer	0.000197	0.000444	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TGFBR2—esophageal cancer	0.000195	0.000441	CbGpPWpGaD
Orlistat—PNLIP—Disease—NOTCH1—esophageal cancer	0.000195	0.00044	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000194	0.000439	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000192	0.000434	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KMT2D—esophageal cancer	0.000192	0.000434	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000192	0.000433	CbGpPWpGaD
Orlistat—FASN—Metabolism—CYP1B1—esophageal cancer	0.00019	0.000429	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CA2—esophageal cancer	0.000187	0.000423	CbGpPWpGaD
Orlistat—FASN—Disease—SMAD4—esophageal cancer	0.000187	0.000422	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKAP13—esophageal cancer	0.000187	0.000422	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SMAD4—esophageal cancer	0.000185	0.000418	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000183	0.000413	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HIF1A—esophageal cancer	0.000183	0.000412	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HIF1A—esophageal cancer	0.000183	0.000412	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000181	0.000408	CbGpPWpGaD
Orlistat—FASN—Metabolism—CYP19A1—esophageal cancer	0.000179	0.000403	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	0.000179	0.000403	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000178	0.000402	CbGpPWpGaD
Orlistat—PNLIP—Disease—CREBBP—esophageal cancer	0.000176	0.000398	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KDR—esophageal cancer	0.000175	0.000394	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KDR—esophageal cancer	0.000175	0.000394	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ADH7—esophageal cancer	0.000174	0.000393	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PLCE1—esophageal cancer	0.000174	0.000393	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	0.000173	0.00039	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000172	0.000389	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000171	0.000387	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ABL1—esophageal cancer	0.000171	0.000386	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PDE4D—esophageal cancer	0.000171	0.000386	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—PIK3CA—esophageal cancer	0.000171	0.000385	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	0.000167	0.000378	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NOTCH1—esophageal cancer	0.000164	0.000371	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NOTCH1—esophageal cancer	0.000164	0.000371	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	0.000164	0.000371	CbGpPWpGaD
Orlistat—FASN—Metabolism—HMOX1—esophageal cancer	0.000163	0.000368	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—GNG7—esophageal cancer	0.000162	0.000367	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.00016	0.000361	CbGpPWpGaD
Orlistat—PNLIP—Disease—NOS3—esophageal cancer	0.000158	0.000357	CbGpPWpGaD
Orlistat—PLA2G4A—Phospholipid metabolism—PIK3CA—esophageal cancer	0.000158	0.000356	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—WWOX—esophageal cancer	0.000157	0.000354	CbGpPWpGaD
Orlistat—FASN—Metabolism—ABCB1—esophageal cancer	0.000156	0.000353	CbGpPWpGaD
Orlistat—FASN—Disease—HIF1A—esophageal cancer	0.000153	0.000345	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ADH1B—esophageal cancer	0.000153	0.000345	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HIF1A—esophageal cancer	0.000151	0.000342	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CREBBP—esophageal cancer	0.000149	0.000337	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CREBBP—esophageal cancer	0.000149	0.000337	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FKBP1A—esophageal cancer	0.000149	0.000336	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—CREBBP—esophageal cancer	0.000148	0.000334	CbGpPWpGaD
Orlistat—PNLIP—Disease—ERBB2—esophageal cancer	0.000148	0.000334	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000147	0.000333	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—EGFR—esophageal cancer	0.000147	0.000331	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—EGFR—esophageal cancer	0.000147	0.000331	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TYMP—esophageal cancer	0.000146	0.00033	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—WIF1—esophageal cancer	0.000146	0.000329	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KDR—esophageal cancer	0.000145	0.000327	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTGS2—esophageal cancer	0.000145	0.000326	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	0.000143	0.000323	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL2—esophageal cancer	0.000143	0.000323	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP26A1—esophageal cancer	0.000142	0.000321	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.00014	0.000316	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—PIK3CA—esophageal cancer	0.00014	0.000316	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—PIK3CA—esophageal cancer	0.00014	0.000316	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	0.00014	0.000316	CbGpPWpGaD
Orlistat—FASN—Disease—NOS2—esophageal cancer	0.000139	0.000314	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000139	0.000313	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ALOX15—esophageal cancer	0.000138	0.000312	CbGpPWpGaD
Orlistat—FASN—Disease—NOTCH1—esophageal cancer	0.000138	0.000311	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NOTCH1—esophageal cancer	0.000136	0.000308	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000134	0.000303	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NOS3—esophageal cancer	0.000134	0.000302	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NOS3—esophageal cancer	0.000134	0.000302	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—ANXA1—esophageal cancer	0.000133	0.000301	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—NOS3—esophageal cancer	0.000132	0.000299	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTO1—esophageal cancer	0.000132	0.000298	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TPI1—esophageal cancer	0.000132	0.000298	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000131	0.000297	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—SST—esophageal cancer	0.000129	0.000292	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—PIK3CA—esophageal cancer	0.000127	0.000287	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—PIK3CA—esophageal cancer	0.000127	0.000287	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ALDOB—esophageal cancer	0.000127	0.000286	CbGpPWpGaD
Orlistat—PNLIP—Disease—CDKN1A—esophageal cancer	0.000126	0.000285	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—GHRL—esophageal cancer	0.000126	0.000285	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PFN1—esophageal cancer	0.000126	0.000284	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ERBB2—esophageal cancer	0.000125	0.000282	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—ERBB2—esophageal cancer	0.000125	0.000282	CbGpPWpGaD
Orlistat—FASN—Disease—CREBBP—esophageal cancer	0.000125	0.000282	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CREBBP—esophageal cancer	0.000124	0.000279	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NOS2—esophageal cancer	0.000123	0.000278	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GAPDH—esophageal cancer	0.000122	0.000275	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	0.000122	0.000275	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTGS2—esophageal cancer	0.000121	0.000273	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CRABP1—esophageal cancer	0.000121	0.000273	CbGpPWpGaD
Orlistat—PNLIP—Disease—EP300—esophageal cancer	0.00012	0.000271	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	0.000118	0.000267	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	0.000118	0.000266	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GNG7—esophageal cancer	0.000115	0.000259	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ELMO1—esophageal cancer	0.000113	0.000255	CbGpPWpGaD
Orlistat—FASN—Disease—NOS3—esophageal cancer	0.000112	0.000252	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000112	0.000252	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—CREBBP—esophageal cancer	0.000111	0.00025	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NOS3—esophageal cancer	0.000111	0.00025	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCND1—esophageal cancer	0.00011	0.000249	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKAP13—esophageal cancer	0.00011	0.000249	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCND1—esophageal cancer	0.00011	0.000249	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00011	0.000249	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	0.000108	0.000244	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ALDH2—esophageal cancer	0.000108	0.000243	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CDKN1A—esophageal cancer	0.000107	0.000241	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CDKN1A—esophageal cancer	0.000107	0.000241	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000105	0.000237	CbGpPWpGaD
Orlistat—PNLIP—Disease—MYC—esophageal cancer	0.000105	0.000237	CbGpPWpGaD
Orlistat—FASN—Metabolism—CREBBP—esophageal cancer	0.000105	0.000236	CbGpPWpGaD
Orlistat—FASN—Disease—ERBB2—esophageal cancer	0.000105	0.000236	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000104	0.000234	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ERBB2—esophageal cancer	0.000103	0.000234	CbGpPWpGaD
Orlistat—PNLIP—Disease—EGFR—esophageal cancer	0.000102	0.000231	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTT1—esophageal cancer	0.000102	0.000231	CbGpPWpGaD
Orlistat—FASN—Disease—PTGS2—esophageal cancer	0.000102	0.000231	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000102	0.00023	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EP300—esophageal cancer	0.000102	0.000229	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EP300—esophageal cancer	0.000102	0.000229	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP2A6—esophageal cancer	0.000101	0.000228	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PDE4D—esophageal cancer	0.000101	0.000228	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000101	0.000228	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—EP300—esophageal cancer	0.000101	0.000227	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NOS3—esophageal cancer	9.91e-05	0.000224	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GNG7—esophageal cancer	9.6e-05	0.000217	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS1—esophageal cancer	9.59e-05	0.000217	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ENO1—esophageal cancer	9.59e-05	0.000217	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PSME2—esophageal cancer	9.45e-05	0.000213	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PSME1—esophageal cancer	9.45e-05	0.000213	CbGpPWpGaD
Orlistat—FASN—Metabolism—NOS3—esophageal cancer	9.36e-05	0.000211	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCND1—esophageal cancer	9.14e-05	0.000206	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—XIAP—esophageal cancer	8.99e-05	0.000203	CbGpPWpGaD
Orlistat—FASN—Disease—CDKN1A—esophageal cancer	8.94e-05	0.000202	CbGpPWpGaD
Orlistat—PNLIP—Disease—PIK3CA—esophageal cancer	8.89e-05	0.000201	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MYC—esophageal cancer	8.85e-05	0.0002	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MYC—esophageal cancer	8.85e-05	0.0002	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CDKN1A—esophageal cancer	8.84e-05	0.0002	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EGFR—esophageal cancer	8.66e-05	0.000195	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EGFR—esophageal cancer	8.66e-05	0.000195	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—esophageal cancer	8.56e-05	0.000193	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CTNNA1—esophageal cancer	8.51e-05	0.000192	CbGpPWpGaD
Orlistat—FASN—Disease—EP300—esophageal cancer	8.5e-05	0.000192	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL2—esophageal cancer	8.46e-05	0.000191	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EP300—esophageal cancer	8.42e-05	0.00019	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.25e-05	0.000186	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP1B1—esophageal cancer	8.15e-05	0.000184	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PSME2—esophageal cancer	7.9e-05	0.000178	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PSME1—esophageal cancer	7.9e-05	0.000178	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ANXA1—esophageal cancer	7.86e-05	0.000178	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP19A1—esophageal cancer	7.67e-05	0.000173	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SST—esophageal cancer	7.65e-05	0.000173	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—EP300—esophageal cancer	7.54e-05	0.00017	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PIK3CA—esophageal cancer	7.51e-05	0.00017	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PIK3CA—esophageal cancer	7.51e-05	0.00017	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOTCH3—esophageal cancer	7.45e-05	0.000168	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GHRL—esophageal cancer	7.45e-05	0.000168	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PIK3CA—esophageal cancer	7.45e-05	0.000168	CbGpPWpGaD
Orlistat—FASN—Disease—MYC—esophageal cancer	7.41e-05	0.000167	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MYC—esophageal cancer	7.33e-05	0.000166	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FBXW7—esophageal cancer	7.33e-05	0.000166	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—esophageal cancer	7.27e-05	0.000164	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—esophageal cancer	7.27e-05	0.000164	CbGpPWpGaD
Orlistat—FASN—Disease—EGFR—esophageal cancer	7.25e-05	0.000164	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EGFR—esophageal cancer	7.17e-05	0.000162	CbGpPWpGaD
Orlistat—FASN—Metabolism—EP300—esophageal cancer	7.12e-05	0.000161	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HMOX1—esophageal cancer	6.99e-05	0.000158	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.86e-05	0.000155	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ABCB1—esophageal cancer	6.71e-05	0.000152	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOTCH2—esophageal cancer	6.69e-05	0.000151	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CA—esophageal cancer	6.29e-05	0.000142	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CA—esophageal cancer	6.23e-05	0.000141	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—esophageal cancer	6.02e-05	0.000136	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFBR2—esophageal cancer	5.93e-05	0.000134	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—BLVRB—esophageal cancer	5.64e-05	0.000127	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC52A3—esophageal cancer	5.64e-05	0.000127	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SMAD4—esophageal cancer	5.61e-05	0.000127	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CA—esophageal cancer	5.58e-05	0.000126	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—esophageal cancer	5.39e-05	0.000122	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CA—esophageal cancer	5.27e-05	0.000119	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.08e-05	0.000115	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC10A2—esophageal cancer	4.8e-05	0.000108	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CA1—esophageal cancer	4.8e-05	0.000108	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HIF1A—esophageal cancer	4.59e-05	0.000104	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CREBBP—esophageal cancer	4.49e-05	0.000101	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KDR—esophageal cancer	4.39e-05	9.92e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CA2—esophageal cancer	4.39e-05	9.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOTCH1—esophageal cancer	4.14e-05	9.34e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ADH7—esophageal cancer	4.08e-05	9.21e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PLCE1—esophageal cancer	4.08e-05	9.21e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NOS3—esophageal cancer	4.02e-05	9.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CREBBP—esophageal cancer	3.75e-05	8.47e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EGFR—esophageal cancer	3.69e-05	8.33e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—esophageal cancer	3.67e-05	8.3e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ADH1B—esophageal cancer	3.58e-05	8.07e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TYMP—esophageal cancer	3.42e-05	7.72e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOS3—esophageal cancer	3.36e-05	7.59e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP26A1—esophageal cancer	3.32e-05	7.51e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALOX15—esophageal cancer	3.24e-05	7.32e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CA—esophageal cancer	3.2e-05	7.23e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ERBB2—esophageal cancer	3.14e-05	7.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTO1—esophageal cancer	3.09e-05	6.98e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TPI1—esophageal cancer	3.09e-05	6.98e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—EP300—esophageal cancer	3.06e-05	6.9e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.96e-05	6.69e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.85e-05	6.44e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.83e-05	6.38e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCND1—esophageal cancer	2.78e-05	6.27e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GNG7—esophageal cancer	2.69e-05	6.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN1A—esophageal cancer	2.69e-05	6.06e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EP300—esophageal cancer	2.56e-05	5.77e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.52e-05	5.69e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTT1—esophageal cancer	2.4e-05	5.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2A6—esophageal cancer	2.37e-05	5.35e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CA—esophageal cancer	2.26e-05	5.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ENO1—esophageal cancer	2.25e-05	5.07e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.25e-05	5.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MYC—esophageal cancer	2.23e-05	5.03e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PSME2—esophageal cancer	2.21e-05	5e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PSME1—esophageal cancer	2.21e-05	5e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGFR—esophageal cancer	2.18e-05	4.92e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.91e-05	4.31e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CA—esophageal cancer	1.89e-05	4.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—esophageal cancer	1.83e-05	4.13e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.8e-05	4.05e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.64e-05	3.7e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.57e-05	3.55e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.05e-05	2.37e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NOS3—esophageal cancer	9.41e-06	2.12e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—esophageal cancer	8.6e-06	1.94e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—EP300—esophageal cancer	7.16e-06	1.62e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CA—esophageal cancer	5.29e-06	1.2e-05	CbGpPWpGaD
